Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT3J5ZI)

• DTT Name: Cell mediated immunity response (CMIR)
• Gene Name: CMIR
• DTT Type: Successful target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T60810

Molecular Interaction Atlas (MIA) of This DTT

11 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arepanrix	DMVMY7K	Influenza virus infection	1E30-1E32	Approved	[2]
Celtura	DMTIUFA	Influenza virus infection	1E30-1E32	Approved	[3]
Fendrix	DM0LRU9	Hepatitis B virus infection	1E51.0	Approved	[4]
Focetria A(H1N1)	DM2PSBE	Influenza virus infection	1E30-1E32	Approved	[5]
GSK2592984A	DM8QB0T	Influenza virus infection	1E30-1E32	Approved	[6]
H1N1 pandemic influenza A vaccine	DMFUAXT	Influenza virus infection	1E30-1E32	Approved	[7]
H5N1 influenza vaccine	DMMHYLB	Human immunodeficiency virus infection	1C62	Approved	[8]
HEV-239	DMGUC9T	Hepatitis E virus infection	1E50.4	Approved	[9]
Live attenuated influenza vaccine	DMX9PIA	Influenza virus infection	1E30-1E32	Approved	[1]
Polyoxidonium	DMJAOT1	Infectious disease	1A00-CA43.1	Approved	[10]
Quattvaxem	DMGAZHU	Bordetella pertussis infection	1C12.0	Approved	[11]

12 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Grippol Plus	DM71GPM	Influenza virus infection	1E30-1E32	Phase 3	[12]
Grippol TC	DMB34TZ	Influenza virus infection	1E30-1E32	Phase 3	[12]
H1N1 influenza vaccine	DMAXTFO	Influenza virus infection	1E30-1E32	Phase 3	[13]
H5N1 influenza vaccine	DM9CMI3	Influenza virus infection	1E30-1E32	Phase 3	[14]
HB-AS02V	DMQ38JZ	Hepatitis B virus infection	1E51.0	Phase 3	[15]
H5N1 influenza vaccine	DMO4I61	Influenza virus infection	1E30-1E32	Phase 2	[6]
HBV vaccine	DMSMCXN	Hepatitis B virus infection	1E51.0	Phase 2	[16]
LEISH-F1	DMV2YDK	Leishmania infection	1F54.0	Phase 2	[17]
Aflunov	DMMNIBY	Influenza A virus H5N1 infection	1E30	Phase 1/2	[18]
AFO-18	DMSX24U	Human immunodeficiency virus-1 infection	1C62	Phase 1	[19]
CAF-01	DMQ7WJI	Vaccination	N.A.	Phase 1	[20]
GMZ-2	DMD6H8B	Malaria	1F40-1F45	Phase 1	[21]

1 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
H1N1 influenza vaccine	DMWB23S	Influenza virus infection	1E30-1E32	Discontinued in Phase 3	[22]

1 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BioVant	DMVOJ0X	Vaccination	N.A.	Investigative	[23]

References

• [1] Flu myths: dispelling the myths associated with live attenuated influenza vaccine. Mayo Clin Proc. 2008 Jan;83(1):77-84.
• [2] Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development. Brain Behav Immun. 2015 Jul;47:44-57.
• [3] A prospective observational safety study on MF59( ) adjuvanted cell culture-derived vaccine, Celtura( ) during the A/H1N1 (2009) influenza pandemic. Vaccine. 2012 Oct 5;30(45):6436-43.
• [4] Revaccination with Fendrix or HBVaxPro results in better response rates than does revaccination with three doses of Engerix-B in previous non-responders. Vaccine. 2012 Nov 6;30(48):6734-7.
• [5] Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study. BMJ. 2013 Feb 4;346:f393.
• [6] Anti-influenza agents from Traditional Chinese Medicine. Nat Prod Rep. 2010 Jan;27(12):1758-80.
• [7] How Influenza (Flu) Vaccines Are Made. FLU.gov. 2014.
• [8] Comparative clinical trial of vaccines against avian influenza. Zh Mikrobiol Epidemiol Immunobiol. 2007 May-Jun;(3):10-6.
• [9] The development of a recombinant hepatitis E vaccine HEV 239. Hum Vaccin Immunother. 2015;11(4):908-14.
• [10] Effect of polyoxidonium on the phagocytic activity of human peripheral blood leukocytes. Russ J Immunol. 2003 Apr;8(1):53-60.
• [11] Double-blind study comparing the immunogenicity of a licensed DTwPHib-CRM197 conjugate vaccine (Quattvaxem) with three investigational, liquid formulations using lower doses of Hib-CRM197 conjugate. Vaccine. 2005 Feb 25;23(14):1715-9.
• [12] Clinical pipeline report, company report or official report of Petrovax.
• [13] Clinical pipeline report, company report or official report of Sanofi Pasteur.
• [14] Characterization of a whole, inactivated influenza (H5N1) vaccine. Influenza and Other Respiratory Viruses Volume 2, Issue 6, pages 261-266, November 2008.
• [15] Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Hum Vaccin. 2010 Jul;6(7):578-84.
• [16] ClinicalTrials.gov (NCT00508833) Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' Candidate Adjuvanted Vaccines (287615). U.S. National Institutes of Health.
• [17] A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine. 2011 Apr 27;29(19):3531-7.
• [18] Aflunov( ): a prepandemic influenza vaccine. Expert Rev Vaccines. 2012 Feb;11(2):145-57.
• [19] ClinicalTrials.gov (NCT01009762) Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection. U.S. National Institutes of Health.
• [20] Mechanisms of Action of Adjuvants. Front Immunol. 2013; 4: 114.
• [21] Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations. Malar J. 2011; 10: 359.
• [22] Risk factors affecting seroconversion after influenza A/H1N1 vaccination in hemodialysis patients. BMC Nephrol. 2012 Dec 3;13:165.
• [23] Calcium Phosphate Nanoparticle Adjuvant. Clin Diagn Lab Immunol. 2000 November; 7(6): 899-903.